GSK share price rises after EU clears Arexvy for adults 18+ as earnings near
GSK shares rose 0.7% in early London trading Tuesday after the EU approved expanding Arexvy’s RSV vaccine label to all adults 18 and over. The move widens access beyond older and high-risk groups. Investors are awaiting GSK’s Feb. 4 earnings for updates on vaccine demand and 2026 guidance.